University of Cambridge spinout T-Therapeutics has raised a further £24 million, extending its Series A round to £70m. The funding is set to accelerate the development of the company’s next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune diseases. It includes new backing from BGF and Tencent, with existing major shareholders Sofinnova Partners, F-Prime … Continue reading BGF backs Cambridge spinout as Series A reaches £70m